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Summary
Objective: Intraarticular Na-Hyaluronate (HA) exerts a beneficial effect on adolescent rabbits after fibronectin fragment (Fn-f) mediated
cartilage injury. We extended our studies to a population of rabbits which have reached full skeletal maturity.
Design: Adult male NZW rabbits received an injury with Fn-f and no further treatment; an injection of HA followed by Fn-f injury, or Fn-f injury
followed by a single or weekly intraarticular injection of HA. All animals were sacrificed 38 days after receiving the Fn-f injury. After sacrifice,
proteoglycan (PG) content was determined from articular cartilage from the medial femoral condyles and tibial plateaus. The patellae were
processed for histology.
Results: Cartilage PG contents were significantly reduced after Fn-f injection (P=0.0167) and were only slightly improved with HA
pre-treatment. However, post-treatment with HA resulted in significant improvements in cartilage PG content when compared to Fn-f only
(single HA, P=0.01; weekly HA, P=0.01). Loss of Safranin-O staining, cell loss, osteophyte formation and inflammation were present in the
patellae following Fn-f injection. Pre-treatment with HA reduced these changes. More significant protection of cartilage and restoration of Fn-f
injury were noted in animals receiving post-treatment with HA.
Conclusions: These results suggest that 38 days after Fn-f injury the lost PG content induced by Fn-f injection is substantially restored by
weekly post-treatment with intraarticular HA in rabbits that have reached full skeletal maturity. © 2003 Published by Elsevier Science Ltd on
behalf of OsteoArthritis Research Society International.
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We have demonstrated that administration of a commer-
cially available form of hyaluronic acid (HA) reduces
fibronectin fragment (Fn-f) mediated bovine cartilage chon-
drolysis1 and human knee cartilage chondrolysis2 in vitro.
We have also reported that HA has some reparative
potential and exerts a beneficial effect on adolescent
rabbits days after an Fn-f mediated cartilage injury3. These
results suggested that HA has a prophylactic effect in this
model of Fn-f-induced articular cartilage injury by promot-
ing the restoration of proteoglycans (PGs) that had been
lost from the tissue. However, spontaneous restoration of
lost matrix PGs following intraarticular Fn-fs can occur in
younger animals4. Subsequently, we have shown that
restoration of lost PGs does not occur to any significant
degree during the 4–5 weeks after the induction of the
Fn-f-mediated injury in adult rabbits that have reached
skeletal maturity5. This finding is consistent with the view44that with aging, articular cartilage has a diminished capacity
to restore lost matrix macromolecules.
HA is a biologic material that has received a great deal of
interest as a potential agent of therapeutic intervention in
arthritis. HA forms the backbone to which cartilage PG is
attached via an HA binding region6 thus forming the mac-
romolecule aggrecan. HA is also a major component of
synovial fluid7 and plays a central role in the formation
of the synovial joint8. High molecular weight HA has been
used in the treatment of human9–15 and animal osteo-
arthritis (OA)16–23. An ameliorative effect of HA has also
been demonstrated in a papain-induced model of articular
cartilage injury in guinea pigs24 and rabbits25. Intraarticular
injections of HA effectively coat the articular surface of
otherwise normal, intact articular cartilage26. In contrast,
treatment with HA of cartilage where the surface has been
disrupted results in deeper penetration of HA into the
crevices formed by the surface fibrillation and deeper
penetration into the cartilage matrix. The biologic signifi-
cance of this observation is not known. The observation
that HA can cover the articular surface might suggest that
HA acts as a prophylactic barrier against agents (e.g.
cytokines), which induce matrix degradation. However, the
major beneficial effect of HA may not be simply as a
physical barrier but as a mediator of enhanced anabolic
processes. For example, it has been reported that in
cultured human explants, HA can restore PG content
Osteoarthritis and Cartilage, Vol. 11, No. 1 45Methods
ANIMALS AND EXPERIMENTAL GROUPS
Adult skeletally mature male New Zealand White rabbits
(10–11 months of age) were housed individually in cages
provided in the Comparative Research Center at The Rush
Presbyterian St Luke’s Medical Center (IACUC #95074).
Animals were fed Purina Rabbit Chow and food intake
monitored daily. Forty-six animals were randomly assigned
to five groups (Table I). Determination of the experimental
groups and the number of animals per group were deter-
mined in consultation with a biostatistician at the investi-
gators’ institution. An original group size of 10 animals per
group was planned. However, animal deaths not related to
the study resulted in fewer animals for some groups as
noted in Table I. Animals were anesthetized after which
they received a single injection of 1 M Fn-f into the left
knee. Intraarticular injections of HA (0.3 ml of a 10 mg/ml
solution: molecular weight 800 000 Da; herein referred to
as HA/800) were carried out in a similar fashion. The
HA/800 was extracted from chicken combs and was
supplied by the Seikagaku Corporation (Tokyo, Japan).
The right non-injected knee served as a control. An
additional 10 animals served as untreated controls. As
noted more completely in Table I injected animals received
a single intraarticular injection of Fn-f and no further treat-
ment, an intraarticular injection of HA/800 followed 3 days
later by an Fn-f injection, an intraarticular injection of Fn-f
followed 3 days later by a single injection of HA/800, or an
intraarticular injection of Fn-f followed 3 days later by a 5
weekly intraarticular injections of HA/800. Animals weresacrificed 38 days after receiving the Fn-f injection. After
sacrifice the patellae were processed for histology and
stained with Safranin-O to demonstrate matrix PGs and
counterstained with fast green30 or with hematoxylin
and eosin. Histologic parameters were used to determine a
Composite Histology Score for comparing changes in the
patellae. Cartilage PG content was determined from full
thickness shavings of articular cartilage from the medial
femoral condyles and medial tibial plateaus.ISOLATION OF RABBIT FN-F
Rabbit plasma was purchased from Pell-Freeze and Fn
purified by adsorption to gelatin-Sepharose as modified28
and Fn-f isolated. Fn-fs from rabbit plasma Fn were gener-
ated from sequential cathepsin D and thrombin digests and
a mixture of the two most potent Fn-fs, the 29-kDa and
50-kDa Fn-f, were tested. This mixture (approximately 1:1
molar ratio) is denoted as the Fn-f. The mixture, when
assayed at 0.1 M was found to have no detectable activity
toward casein or several synthetic serine proteinases sub-
strates assayed as described4 or activity toward gelatin,
assayed by gelatin zymography. Immediately prior to
injection, the Fn-f solutions were dialysed against 50 mM
phosphate, 100 mM NaCl, pH 7.0, without protease
inhibitors and sterile-filtered.INJECTION PROCEDURE
Animals were anesthetized by an intra-muscular injec-
tion of a mixture of ketamine (80 mg/cc; Abbot Labora-
tories, North Chicago, IL) and acepromazine (2.0 mg/cc;
Phoenix Pharmaceuticals, St Josephs, MO) at a dose of
1.0 cc/1.5 kg body weight after which the left knee was
washed with 70% isopropyl alcohol. Intraarticular injections
were performed under aseptic conditions by passing a
26-gauge needle attached to a tuberculin syringe through
the joint capsule lateral to the patellar tendon. Injected
joints were moved through a few extension/flexion move-
ments to ensure equal distribution of the injected materials
throughout the joint cavity. Animals were then placed in
their pens and permitted to recover from the anesthetic. All




0 1 3 . . . 10 17 24 31 38 . . . 41
Untreated injury 10 f Sacrifice
Pre-injury HA/800 8 + f Sacrifice
Post-injury HA/800 9 f + Sacrifice
Post-injury HA/800 10 f + + + + + Sacrifice
Untreated control 9 Sacrifice
f—0.3 ml fibronectin fragment at 1 M 29/50 kD.
+—0.3 ml of a 10 mg/ml HA (about 800 kDa) solution in sterile saline.ANALYTICAL PROCEDURES
Both knees were opened immediately after sacrifice and
examined grossly. Full thickness shavings of articular car-
tilage from the central, habitually loaded region of thein damaged cartilage and this is associated with enhanced
PG synthesis2.
We have utilized an animal model to test the efficacy of
HA. Injection of Fn-f into rabbit knee joints has been shown
to rapidly enhance loss of PG within a few days4. We have
recently reported that the injection enhances levels of
MMPs and temporarily suppresses synthesis of PG in the
injected joint27. This model was used by us to demonstrate
that HA decreased Fn-f mediated cartilage matrix PG
depletion in adolescent animals. We have now extended
our studies to a population of rabbits that have reached full
skeletal maturity. This study has particular relevance to the
use of HA/800 in humans since the vast majority of patients
receiving HA/800 therapy have reached skeletal maturity.
The design of this study was to (1) determine if HA/800 can
block Fn-f mediated damage in the knee joints of skeletally
mature rabbits and (2) determine if HA/800 administered
following the Fn-f-mediated injury can enhance the
restoration of matrix PGs lost from the articular matrix.
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obtained for determination of PG content. Cartilage
samples were weighed and then digested in 1.0 ml of
50 mM phosphate buffer, pH 6.0, containing 10 mM EDTA,
10 mM cysteine and 27 g/ml papain for 8 h at 60°C. The
digests were then subjected to the DMB assay as
described in modified form29. Thus, cartilage PG content
was expressed as g PG/mg cartilage wet weight. In order
to rule out possible systemic effects of Fn-f injury, all
contralateral noninjected knee PG contents were com-
pared for significant differences. The mean PG content
value for the right contralateral knees of all groups studied
was 34.3±8.5 and there were no differences among these
groups. Cartilage PG contents were then expressed as a %
of the contralateral control knee and examined for differ-
ences among the groups. The PG content data were
analysed by a one-way analysis of variance followed by
post-hoc Bonferroni corrected t-tests to determine which
specific differences were significant. For histology, samples
of the patellae, including the parapatellar synovium, were
fixed for one week in 10% neutral buffered formalin con-
taining 5% cetyl pyridinium chloride, decalcified in formic
acid: sodium citrate (44% formic acid: 20% sodium citrate)
for two weeks and embedded in paraffin. Microscopic
sections (8 m) of the samples were stained with
Safranin-O to demonstrate matrix PGs and counterstained
with fast green30 or with hematoxylin and eosin. Sections
from the left (injected) knees and the untreated control right
knees of each experimental animal were stained concur-
rently to control for variations in uptake of the stain. A
previously published scoring method31 was used to quan-
tify histologic change using 6 parameters (articular surface,
Safranin-O staining, cell loss, cell clusters, osteophytes,
synovial membrane). Scoring was made for sections while
blinded to the reader and later summarized for compari-
sons. The patellar histology scores were analysed by the
Kruskal–Wallis test followed by Mann–Whitney tests to
determine which specific differences were significant.Results
All animals were maintained in good general health, ate
and drank a normal amount and had no noticeable differ-ences in physical activity when compared with similar
animals involved in other studies but maintained in the
same room. Animals ranged in ages from 10.0 to 11.8
months and weighed 4.2+0.4 kg. Animals exhibited a nor-
mal weight gain during the study. All joints that received
intraarticular Fn-f were slightly swollen but were normal 3
days after the injection. On day 38, knees from animals
injected with Fn-f were grossly normal. All contralateral
non-injected right knees and knees from untreated control
animals were normal in every respect throughout the entire
experiment.CARTILAGE PG CONTENT
Cartilage PG content levels were significantly reduced
(71%+12 of control knee; mean+S.D.; P=0.001) 38 days
after Fn-f injection in animals not receiving HA/800 treat-
ment (Fig. 1). Cartilage PG content levels remained simi-
larly reduced 38 days after Fn-f injection in animals
pretreated with HA/800 (84%+11), and in animals that
received a single HA/800 post-treatment injection following
Fn-f injury (86%+10). In contrast, weekly HA/800 post-
treatment injections following Fn-f injury resulted in
significantly restored cartilage PGs (90%+12; P=0.017).
There was a significant group effect for the PG data
(P<0.001 in the analysis of variance). Figure 1 shows
means and standard deviations of the five groups. The
untreated control PG mean was significantly higher than
the means for the injury only (no HA/800 treatment) group
(P<0.001), the pre-injury single HA/800 treatment group
(P=0.032) and the post-injury single HA/800 treatment
group (P=0.037), but was not different from the post-injury
weekly HA/800 treatment group (P=0.194). For all groups
of animals injected with Fn-f, only the post-injury weekly
HA/800 treatment group had a higher mean than the
untreated Fn-f injury group (P=0.017) and was not
statistically different from the untreated control group.Fig. 1. Articular cartilage proteolgycan content from the medial femoral condyle and tibial plateau expressed as a percent of the contralateral
knee. Data is expressed as percent±S.D. Letters refer to statistical measures as follows: (a) different from the intact untreated control group
P=0.001; (b) different from the post-injury HA (weekly injection) group P=0.017; (c) different from the intact untreated control group P=0.032;
(d) different from the intact untreated control group P=0.037.HISTOLOGY OF PATELLA
No histologic changes were noted in the right contralat-
eral non-injected knees of any animals in the groups
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Histologic analyses of the patellae
Group Safranin-O loss Cell loss Fibrillation Osteophytes Inflammation
Injury only 2/10 none 7/10 (<25%) None 4/10 3/10



















Untreated controls 9/9 none None None NoneFig. 2. Composite histologic scores of patellae expressed as total composite score±S.D. Letters refer to statistical measures as follows: (a)
different from the intact untreated control group P=0.001; (b) different from the post-injury HA (single injection) group P=0.0040; (c) different
from the post-injury HA (weekly injection) group P=0.0042; (d) different from the intact untreated control group P=0.01.studied. Loss of Safranin-O, indicating loss of cartilage
PGs, ranged from none to marked in all groups receiving
Fn-f injection (Table II). In general, Fn-f injected groups
receiving no HA/800 treatment had a higher number of
animals with more pronounced PG loss. Animals receiving
pre-treatment with HA/800 had less PG staining loss sug-
gesting partial restoration of lost cartilage PGs. Restoration
of PGs was greatest in animals receiving HA/800 treatment
after Fn-f injection. Only three of 10 animals 38 days after
Fn-f injection and no treatment exhibited significant cell
loss. Cell loss was not noted in any other animals. Surface
fibrillation was not noted in any animal. Osteophytes, which
consisted of a small bud of cartilage at the joint margin,
were noted in four of 10 animals 38 days after Fn-f injection
and no HA/800 treatment. Osteophytes were seen in two of
eight animals pre-treated with HA/800, no animals receiv-ing a single post-treatment of HA/800 and only one of 10
animals receiving weekly post-treatment HA/800. Inflam-
mation of the synovial membrane was noted in three of 10
animals 38 days after Fn-f injection and in no animals
receiving HA/800 treatment. Composite patella scores
were highest (indicating more damage) in animals 38 days
after Fn-f injection and no HA/800 treatment (Fig. 2).
Pre-treatment with HA/800 before Fn-f injection slightly
reduced the composite patella score. Post-treatment
(single or weekly injections) with HA/800 following Fn-f
injection had the greatest improvement on composite
patella scores.
There was a significant group effect for the composite
patella score data (P<0.001 in the Kruskal–Wallis test).
Figure 2 shows medians and ranges. The mean composite
patella histology score for the group receiving Fn-f injury
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untreated control group (P=0.001), the post-injury HA
(single injection) treatment group (P=0.004) and the post-
injury HA (weekly injection) treatment group (P=0.0042).
The mean composite patella histology score for the pre-
injury treatment group was not different from the group
receiving Fn-f injury with no treatment, but was different
from the intact untreated control group (P=0.01). Thus,
both the post-injury single HA/800 and weekly HA/800
treatments reduced cartilage changes induced by Fn-f
injury.Discussion
We have reported that with adolescent rabbits, injected
HA/800 can block the catabolic insult caused by Fn-f 2, a
class of mediator which has been shown to up-regulate
MMPs and greatly enhance degradation and loss of PG
from bovine or human explants. Further, it was shown that
Fn-fs up-regulate MMP-3 and temporarily suppress PG
synthesis in the injected knee in a dose-dependent fashion
in this model27. This study was designed to determine if
HA/800 can block Fn-f mediated damage in the knee joints
of skeletally mature rabbits and to determine if HA/800
administered following the Fn-f-mediated injury can
enhance the restoration of matrix PGs lost from the articu-
lar matrix. Pre-treatment of cartilage slices in vitro with HA
has been shown to block Fn-f-induced PG loss1. Similarly,
pre-treatment of adolescent rabbits with intraarticular HA
reduced Fn-f-mediated PG loss3. In the present study,
pretreatment of older, skeletally mature rabbits had no
effect on Fn-f-mediated cartilage injury in the femoral
condyles or tibial plateaus suggesting that HA may work in
this model of older animals by enhancing PG synthesis of
damaged cartilage. MMP-3 is up-regulated in the injected
knee joint cartilage of mature rabbits but not in control
knees and PG synthesis is suppressed to 50% of control
levels by day 2 (data not shown). This PG depletion and
MMP-production peaks early as a damage pulse, followed
by an attempted rebound. These catabolic events are
maximal by day 2. This would correspond to 1 day prior to
administration of HA in the post-treatment groups in this
study.
While many of the in vivo animal model tests and in vitro
testing with cartilage explants of the chondroprotective
activities of HA suggest that HA has beneficial effects,
clinical studies have not yet clearly demonstrated efficacy
in terms of structural alteration, although pain alleviation in
the human subjects is clear32. Since the cartilage substrate
used for in vivo and in vitro testing is typically derived from
younger animals, while the typical patient population used
in tests of clinical HA is of older patients, a possible
explanation for differences in beneficial effects may be that
HA loses effectiveness as cartilage ages. This, in turn,
could be due to a number of factors, including age related
decreases in cell vitality or anabolic responses or increases
in responses of cartilage to catabolic insults, such as
increased catabolic cytokine or MMP levels. Aged related
changes in the matrix may also modify responses of cells to
external stimuli.
The effects of intraarticular Fn-f appear to be less on the
patellofemoral articulation than on the cartilage on the
medial femoral condyle and tibial plateau. Histologic
changes on the patellae were less than would be expected
based on biochemical changes (i.e. PG loss) in femoral
condyle and tibial plateau cartilage, which may reflect thedifferences in forces acting on the two joints. The femur/
tibia articulation is subject to higher and more direct impact
loading while the cartilage of the patellofemoral articulation
receives primarily a gliding load with some compression of
the articular surfaces. Thus, PG loss (as reflected by
Safranin-O staining) varied more widely following Fn-f
injury. Pre-treatment prior to Fn-f injury as well as post-
treatment with HA following Fn-f injury did reduce the
severity of PG loss histologically as well as cell loss,
osteophyte formation and inflammation. The most dramatic
effects were noted, however, with post-treatment.
Our original analysis of HA-treated adolescent rabbits
focused on PG content only. In this work we have extended
our analysis to include other parameters. We did not expect
there would be an absolute correlation between PG content
and the other parameters, especially since PG content is
only one component of the collective parameters. None the
less, both types of analysis do support the efficacy of HA.
We conclude that HA is effective on skeletally mature
rabbits. Interestingly, HA has also been shown to be
effective on blocking Fn-f mediated damage to cartilage
from 6-year-old bovines (Homandberg et al., personal
communication). Thus, it is unlikely that cartilage from older
animals is incapable of responding to HA treatment. Based
on these results and in extrapolation to human trials, it is
imperative to question why injection of HA into human
patients does not result in structural modification as
reported here for animal tissue.References
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